Detalhe da pesquisa
1.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Blood
; 141(20): 2470-2482, 2023 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821767
2.
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
Blood
; 138(22): 2278-2289, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34265047
3.
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.
J Oncol Pharm Pract
; 29(1): 45-51, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34816754
4.
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
Transpl Infect Dis
; 21(5): e13145, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31301099
5.
Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.
Biol Blood Marrow Transplant
; 23(4): 625-634, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28104514
6.
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 21(11): 1921-5, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26033279
7.
Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.
Biol Blood Marrow Transplant
; 21(4): 720-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25555450
8.
A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help.
Blood Adv
; 8(4): 1053-1061, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37467016
9.
The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL.
J Biol Chem
; 287(39): 32875-80, 2012 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22898820
10.
High white blood cell concentration in the peripheral blood stem cell product can induce seizures during infusion of autologous peripheral blood stem cells.
Biol Blood Marrow Transplant
; 18(7): 1055-60, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22178402
11.
Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.
J Oncol Pharm Pract
; 18(1): 17-22, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21228086
12.
Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges.
Hematol Oncol Stem Cell Ther
; 15(3): 159-167, 2022 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36537907
13.
Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States.
J Med Econ
; 25(1): 857-863, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35674411
14.
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086946
15.
Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
Transplant Cell Ther
; 27(6): 504.e1-504.e6, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158154
16.
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
J Clin Oncol
; 39(17): 1888-1898, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33877856
17.
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.
Biol Blood Marrow Transplant
; 15(7): 777-84, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19539208
18.
The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
Am Soc Clin Oncol Educ Book
; 39: 433-444, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31099694
19.
Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma.
Mil Med
; 171(2): 161-5, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16578989
20.
Treatment of Acquired von Willebrand Syndrome and Prevention of Bleeding Postautologous Stem Cell Transplant during Severe Pancytopenia with IVIG.
Case Rep Hematol
; 2015: 809313, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25922770